<DOC>
	<DOCNO>NCT02866383</DOCNO>
	<brief_summary>This prospective , randomize , open-label phase 2 study patient metastatic PC refractory intolerant least one line prior systemic chemotherapy gemcitabine platinum-containing regimen determine efficacy safety nivolumab nivolumab plus ipilimumab administer concurrently high dose RT . Patients metastatic PC feasible candidate radiation biopsy primary and/or metastatic lesion include .</brief_summary>
	<brief_title>Immune Checkpoint Inhibition Combination With Radiation Therapy Pancreatic Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>Signed informed consent Subjects must sign dated IRB/IEC approve write informed consent form accordance regulatory institutional guideline . This must obtain performance protocol relate procedure part normal subject care Subjects must willing able comply schedule visit , treatment schedule , laboratory testing , requirement study Histopathological confirmation pancreatic adenocarcinoma prior enter study OR histopathological confirmation carcinoma set clinical radiological characteristic , together pathology , consistent diagnosis PC At least one measurable primary insitu ( locallyrecurrent ) metastatic tumor must present , opinion radiation oncologist , amenable RT plan protocol least one additional metastatic tumor undergo RT measurable accord RECIST 1.1 criterion . Both lesion must accessible imageguided percutaneous biopsy There upper limit number prior chemotherapy regimens receive . Patients must receive failed intolerance least one line prior systemic chemotherapy gemcitabine platinumcontaining regimen unresectable and/or metastatic PC Age &gt; 18 year old Life expectancy great 3 month ECOG/WHO Performance Status ( PS ) 01 Patients must normal organ marrow function define : White blood cell count ( WBC ) ≥ 2 x 10⁹/L Absolute neutrophil count ( ANC ) ≥ 1.5 x 10⁹/L Hemoglobin ≥ 5,6 mmol/l Platelet count ≥ 100 x 10⁹/L Serum bilirubin ≤ 1.5 x upper limit normal ( ULN ) ( patient Gilbert 's Syndrome must total bilirubin &lt; 3.0 mg/dL ) ASAT/ALAT ≤ 3 x ULN ( &lt; 5 x ULN know liver metastasis ) PP ≥ 40 INR ≤ 1.5 Serum creatinine ≤ 1.5 x ULN CrCl ≥ 40 mL/min ( use CockcroftGault formula ) Women childbearing potential ( WOCBP ) must use method ( ) contraception indicate per protocol . For teratogenic study drug and/or insufficient information ass teratogenicity ( preclinical study do ) , highly effective method ( ) contraception ( failure rate le 1 % per year ) require . The individual method contraception duration determine consultation investigator . WOCBP must follow instruction birth control halflife investigational drug great 24 hour , contraception continue period 30 day plus time required investigational drug undergo five halflives . The halflife nivolumab ipilimumab 25 day 18 day , respectively . WOCBP therefore use adequate method avoid pregnancy 23 week ( 30 day plus time require nivolumab undergo five halflives ) last dose investigational drug . WOCBP must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 24 hour prior start nivolumab Women must breastfeed Men sexually active WOCBP must use contraceptive method failure rate le 1 % per year The investigator shall review contraception method time period contraception must follow . Men sexually active WOCBP must follow instruction birth control halflife investigational drug great 24 hour , contraception continue period 90 day plus time required investigational drug undergo five halflives . The halflife nivolumab ipilimumab 25 day 18 day , respectively . Men sexually active WOCBP must continue contraception 31 week ( 90 day plus time require nivolumab undergo five half life ) last dose investigational drug . Women childbearing potential ( ie , postmenopausal surgically sterile well azoospermic men require contraception Subjects must sign dated BIOPAC IRB/IEC approve write informed consent form accordance regulatory institutional guideline . This must obtain performance protocol relate procedure part normal subject care Malignant ascites clinically detectable physical examination symptomatic . Evidence radiographic ascites clinically significant exclusion criterion Prior treatment antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , antiCTLA4 antibody , antibody drug specifically target Tcell costimulation checkpoint pathways No chemotherapy , radiotherapy , major surgery within last 2 week prior enter study Any serious uncontrolled medical disorder , opinion investigator , may increase risk associate study participation study drug administration , impair ability subject receive protocol therapy , interfere interpretation study result Patients exclude active , know suspected autoimmune disease . Subjects permit enroll vitiligo , type I diabetes mellitus , residual hypothyroidism due autoimmune condition require hormone replacement , psoriasis require systemic treatment , condition expect recur absence external trigger Patients exclude positive test hepatitis B virus surface antigen ( HBV sAg ) hepatitis C virus ribonucleic acid ( HCV antibody ) indicate acute chronic infection Patients exclude condition require systemic treatment either corticosteroid ( &gt; 10 mg daily prednisone equivalent ) immunosuppressive medication within 14 day study drug administration . Inhaled topical steroid adrenal replacement dos &gt; 10 mg daily prednisone equivalent permit absence active autoimmune disease As potential hepatic toxicity nivolumab nivolumab/ipilimumab combination , drug predisposition hepatoxicity use caution patient treat nivolumabcontaining regimen Patients exclude known history test positive human immunodeficiency virus ( HIV ) know acquired immunodeficiency syndrome ( AIDS ) Allergies Adverse Drug Reaction History allergy study drug component History severe hypersensitivity reaction monoclonal antibody WOCBP pregnant breastfeed Women positive pregnancy test enrollment prior administration study medication Patients exclude active brain metastasis leptomeningeal metastasis . Subjects brain metastasis eligible metastasis treat magnetic resonance imaging ( MRI ) evidence progression [ low minimum 4 week ] treatment complete within 28 day prior first dose nivolumab administration . There must also requirement immunosuppressive dos systemic corticosteroid ( &gt; 10 mg/day prednisone equivalent ) least 2 week prior study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>